Should Investors Follow the 'Sell in May' Strategy?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NVO?
Source: CNBC
- Testing Traditional Strategies: As May begins, investors are challenged by the traditional 'sell in May' strategy, despite historical data showing that the S&P 500 has averaged a 1.5% return in May and a 1.9% increase in June over the past decade.
- Strong European Market Performance: In April, Europe's STOXX 600 and Germany's DAX posted their best monthly performances since January of last year, with Italy's FTSE MIB achieving a nearly 9% rally, indicating market resilience and potential investment opportunities.
- Upcoming Earnings Reports: In the coming weeks, major European banks like Unicredit and HSBC will release earnings, and investors should closely monitor these reports to gauge market trends, as changes in corporate profitability could significantly impact stock performance in the current economic climate.
- Risk Factors Warning: Despite the strong performance of global stocks, the cautious stance of the Federal Reserve and ECB, along with ongoing inflation pressures, may pose threats to the market, prompting investors to make informed choices between traditional and unconventional strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 44.870
Low
42.00
Averages
54.67
High
70.00
Current: 44.870
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Q1 Earnings Preview Amidst Competitive Landscape
- Intensifying Market Competition: Novo Nordisk is set to report Q1 earnings on May 6, with consensus EPS at $1.10 and revenue at $11.26 billion, but three downward revisions in the past three months indicate increasing competitive pressure on its GLP-1 drug franchise.
- Strong Prescription Demand: Early demand for Novo's oral semaglutide (Wegovy) has been robust, with over 600,000 prescriptions written in the first two months, suggesting a potential outpacing of Eli Lilly's competing offerings in the market.
- Pricing Strategy Adjustments: In response to market pressures, Novo plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus by approximately 35%-50%, aiming to expand market share and improve accessibility, although this may compress margins in the short term.
- Strategic Partnership Development: Novo's collaboration with Hims & Hers Health will see the platform offer Novo's branded GLP-1 drugs while discontinuing compounded alternatives, which could reduce gray-market competition and enhance Novo's brand positioning in the market.
See More
Novo Nordisk's Drug Market Entry Delayed
- Data Protection Rights: Novo Nordisk has informed Chinese authorities of its entitlement to data protection rights, which could delay the market entry of off-patent versions of its blockbuster GLP-1 drug Ozempic until next year, impacting the competitive landscape.
- Patent Expiry Context: Although the patent for semaglutide, the active ingredient for Ozempic and its sister drug Wegovy, expired in March in China, Novo Nordisk asserts that under the Sino-Swiss Free Trade Agreement, it is entitled to regulatory data protection until April 2027 in China.
- Regulatory Review Suspension: Hangzhou Jiuyuan Genetic Biopharmaceutical, the first Chinese company seeking regulatory clearance for a semaglutide generic, has had its review suspended due to “data protection provisions under agreements with governments of other countries,” highlighting regulatory uncertainty.
- Industry Warning: Experts argue that this situation serves as a lesson for Chinese drugmakers to strengthen their legal functions to address potential market challenges and legal risks, ensuring compliance and competitiveness in a rapidly evolving market.
See More
Novo Nordisk CEO: Seeking More Deals to Broaden Pipeline
- Active Business Development: Novo Nordisk CEO Mike Doustdar stated that the company is actively seeking deals with other firms that have complementary assets to fulfill its ambition of helping hundreds of millions of patients, demonstrating its strategic commitment in the competitive obesity drug market.
- Market Competition Pressure: Although Novo Nordisk pioneered the GLP-1 weight loss drug market, rival Eli Lilly has surpassed it in market share for weekly GLP-1 injections, highlighting the challenges the company faces in maintaining its leadership position.
- Optimistic Pipeline Outlook: Doustdar expressed optimism about upcoming treatments, particularly mentioning CagriSema and zenagamtide, which are expected to receive approval by the end of the year, indicating Novo Nordisk's strong R&D capabilities within the industry.
- Increased Profit Guidance: Following better-than-expected performance of the Wegovy pill, Novo Nordisk raised its full-year profit guidance, reflecting the company's confidence in future performance, which may attract more investor interest.
See More
Novo Nordisk Actively Pursuing Acquisition Opportunities
- Market Leadership Challenges: CEO Mike Doustdar of Novo Nordisk acknowledges that despite pioneering the GLP-1 weight loss drug market, analysts have raised concerns about the competitiveness of its pipeline, especially as rival Eli Lilly has surpassed its market share.
- Acquisition Intentions Clear: Doustdar emphasizes that Novo Nordisk is actively seeking acquisition opportunities that complement its existing assets to secure its leadership position in the global obesity drug market, with expectations of more deals to come in the near future.
- Pipeline Outlook Optimistic: He highlights that the CagriSema drug candidate is expected to gain approval by the end of the year, while the accelerated development of the zenagamtide drug also shows promising prospects, reflecting the company's confidence in its new drug development efforts.
- Profit Guidance Raised: Following better-than-expected performance of the Wegovy pill in Q1, Novo Nordisk has raised its full-year profit guidance, indicating a positive outlook for future performance and further solidifying its competitive stance in the market.
See More
Market Update: Stocks Rise as Oil Prices Fall
- War Ending Anticipation: Stock futures rose as Axios reported that the Iran war may soon end, with the S&P 500 and Nasdaq hitting record highs yesterday, reflecting investor optimism about economic recovery prospects.
- Aerospace Stock Surge: Travel and aerospace stocks are poised to benefit if the war concludes, with Boeing shares up about 4% and Delta Airlines rising 6%, indicating strong market expectations for a rebound in air travel demand.
- Optical Technology Deal: Corning and Nvidia announced a significant deal, with Corning set to build three new plants, increasing its domestic optical manufacturing capacity tenfold, leading to a 15% surge in Corning's stock, highlighting strong demand for optical technology over copper.
- AI Market Growth: AMD's second-quarter guidance exceeded expectations, predicting the server CPU market will reach $120 billion by 2030, with AMD shares soaring 15%, indicating sustained growth in the semiconductor industry driven by AI technology.
See More
U.S. Stock Futures Rise as Investor Sentiment Improves
- Arista Networks Performance: Despite Arista Networks reporting a first-quarter revenue of $2.71 billion, exceeding Wall Street's $2.62 billion estimate, and earnings per share of $0.87, above the $0.81 forecast, its stock fell about 9% in premarket trading, reflecting market concerns over supply constraints.
- Novo Nordisk Optimism: Novo Nordisk's stock rose 5.98% in premarket trading after the company raised its full-year outlook, expecting a contraction in adjusted sales and operating profit to improve from a previous forecast of a 5% to 13% decline to a new range of 4% to 12%, driven by strong early demand for its oral Wegovy pill.
- AMC Entertainment Recovery: AMC Entertainment's stock increased approximately 8% in premarket trading as it reported a smaller quarterly loss, with revenue climbing 21.7% to $1.05 billion, and net loss narrowing from $202.1 million to $117.1 million year-over-year, while adjusted EBITDA turned positive at $38.3 million, indicating a rebound in moviegoing.
- Restaurant Brands International Performance: Restaurant Brands International topped estimates in its first-quarter earnings report, achieving system-wide sales growth of 6.2% and comparable sales growth of 3.2%, exceeding the consensus expectation of 3.0%, primarily driven by a 5.8% increase in the Burger King segment, showcasing strong performance in the fast-food market.
See More
Novo Nordisk Q1 Earnings Preview Amidst Competitive Landscape
- Intensifying Market Competition: Novo Nordisk is set to report Q1 earnings on May 6, with consensus EPS at $1.10 and revenue at $11.26 billion, but three downward revisions in the past three months indicate increasing competitive pressure on its GLP-1 drug franchise.
- Strong Prescription Demand: Early demand for Novo's oral semaglutide (Wegovy) has been robust, with over 600,000 prescriptions written in the first two months, suggesting a potential outpacing of Eli Lilly's competing offerings in the market.
- Pricing Strategy Adjustments: In response to market pressures, Novo plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus by approximately 35%-50%, aiming to expand market share and improve accessibility, although this may compress margins in the short term.
- Strategic Partnership Development: Novo's collaboration with Hims & Hers Health will see the platform offer Novo's branded GLP-1 drugs while discontinuing compounded alternatives, which could reduce gray-market competition and enhance Novo's brand positioning in the market.
See More
Novo Nordisk's Drug Market Entry Delayed
- Data Protection Rights: Novo Nordisk has informed Chinese authorities of its entitlement to data protection rights, which could delay the market entry of off-patent versions of its blockbuster GLP-1 drug Ozempic until next year, impacting the competitive landscape.
- Patent Expiry Context: Although the patent for semaglutide, the active ingredient for Ozempic and its sister drug Wegovy, expired in March in China, Novo Nordisk asserts that under the Sino-Swiss Free Trade Agreement, it is entitled to regulatory data protection until April 2027 in China.
- Regulatory Review Suspension: Hangzhou Jiuyuan Genetic Biopharmaceutical, the first Chinese company seeking regulatory clearance for a semaglutide generic, has had its review suspended due to “data protection provisions under agreements with governments of other countries,” highlighting regulatory uncertainty.
- Industry Warning: Experts argue that this situation serves as a lesson for Chinese drugmakers to strengthen their legal functions to address potential market challenges and legal risks, ensuring compliance and competitiveness in a rapidly evolving market.
See More
Novo Nordisk CEO: Seeking More Deals to Broaden Pipeline
- Active Business Development: Novo Nordisk CEO Mike Doustdar stated that the company is actively seeking deals with other firms that have complementary assets to fulfill its ambition of helping hundreds of millions of patients, demonstrating its strategic commitment in the competitive obesity drug market.
- Market Competition Pressure: Although Novo Nordisk pioneered the GLP-1 weight loss drug market, rival Eli Lilly has surpassed it in market share for weekly GLP-1 injections, highlighting the challenges the company faces in maintaining its leadership position.
- Optimistic Pipeline Outlook: Doustdar expressed optimism about upcoming treatments, particularly mentioning CagriSema and zenagamtide, which are expected to receive approval by the end of the year, indicating Novo Nordisk's strong R&D capabilities within the industry.
- Increased Profit Guidance: Following better-than-expected performance of the Wegovy pill, Novo Nordisk raised its full-year profit guidance, reflecting the company's confidence in future performance, which may attract more investor interest.
See More
Novo Nordisk Actively Pursuing Acquisition Opportunities
- Market Leadership Challenges: CEO Mike Doustdar of Novo Nordisk acknowledges that despite pioneering the GLP-1 weight loss drug market, analysts have raised concerns about the competitiveness of its pipeline, especially as rival Eli Lilly has surpassed its market share.
- Acquisition Intentions Clear: Doustdar emphasizes that Novo Nordisk is actively seeking acquisition opportunities that complement its existing assets to secure its leadership position in the global obesity drug market, with expectations of more deals to come in the near future.
- Pipeline Outlook Optimistic: He highlights that the CagriSema drug candidate is expected to gain approval by the end of the year, while the accelerated development of the zenagamtide drug also shows promising prospects, reflecting the company's confidence in its new drug development efforts.
- Profit Guidance Raised: Following better-than-expected performance of the Wegovy pill in Q1, Novo Nordisk has raised its full-year profit guidance, indicating a positive outlook for future performance and further solidifying its competitive stance in the market.
See More
Market Update: Stocks Rise as Oil Prices Fall
- War Ending Anticipation: Stock futures rose as Axios reported that the Iran war may soon end, with the S&P 500 and Nasdaq hitting record highs yesterday, reflecting investor optimism about economic recovery prospects.
- Aerospace Stock Surge: Travel and aerospace stocks are poised to benefit if the war concludes, with Boeing shares up about 4% and Delta Airlines rising 6%, indicating strong market expectations for a rebound in air travel demand.
- Optical Technology Deal: Corning and Nvidia announced a significant deal, with Corning set to build three new plants, increasing its domestic optical manufacturing capacity tenfold, leading to a 15% surge in Corning's stock, highlighting strong demand for optical technology over copper.
- AI Market Growth: AMD's second-quarter guidance exceeded expectations, predicting the server CPU market will reach $120 billion by 2030, with AMD shares soaring 15%, indicating sustained growth in the semiconductor industry driven by AI technology.
See More
U.S. Stock Futures Rise as Investor Sentiment Improves
- Arista Networks Performance: Despite Arista Networks reporting a first-quarter revenue of $2.71 billion, exceeding Wall Street's $2.62 billion estimate, and earnings per share of $0.87, above the $0.81 forecast, its stock fell about 9% in premarket trading, reflecting market concerns over supply constraints.
- Novo Nordisk Optimism: Novo Nordisk's stock rose 5.98% in premarket trading after the company raised its full-year outlook, expecting a contraction in adjusted sales and operating profit to improve from a previous forecast of a 5% to 13% decline to a new range of 4% to 12%, driven by strong early demand for its oral Wegovy pill.
- AMC Entertainment Recovery: AMC Entertainment's stock increased approximately 8% in premarket trading as it reported a smaller quarterly loss, with revenue climbing 21.7% to $1.05 billion, and net loss narrowing from $202.1 million to $117.1 million year-over-year, while adjusted EBITDA turned positive at $38.3 million, indicating a rebound in moviegoing.
- Restaurant Brands International Performance: Restaurant Brands International topped estimates in its first-quarter earnings report, achieving system-wide sales growth of 6.2% and comparable sales growth of 3.2%, exceeding the consensus expectation of 3.0%, primarily driven by a 5.8% increase in the Burger King segment, showcasing strong performance in the fast-food market.
See More
